Nanoliposomal technology

We use nanoliposomal technology in our products. What is it and why is it the most effective solution in drug delivery?

Liposomal particles

In terms of chemistry, liposomes are spherical particles of vesicular morphology formed by lipids. These particles are able to encapsulate hydrophilic drugs into their aqueous compartment and incorporate hydrophobic drugs into the lipid membrane. There are also particles called nanoliposomes with the same properties, which are smaller than liposomes. Their diameter must always be no more than 100 nanometres.

Advantages of the technology

Modern medicine uses liposomes and nano liposomes on a daily basis. They have gained attention not only for their use as a model membrane system, but also for their utility during drug delivery, where liposomes and nanoliposomes have key therapeutic advantages in targeting and controlled release of active ingredients.

Liposomes X nanoliposomes

We collaborate with our leading universities, scientific institutions and pharmaceutical companies in the research and manufacture of our nanoliposomal products. The existence of nanoliposomes greatly facilitates drug delivery due to their water solubility and size. Here, the smaller the better. Nanoliposomes are simply absorbed faster and are more readily bioavailable. They are currently the most effective way of delivering medicinal substances to the body.

Based on scientific
evidence

Our products are based on so-called evidence-based medicine (also known as EBM). It is about the use of scientifically proven evidence, which the doctor evaluates as an appropriate way to care for patients. EBM uses up-to-date information that has not yet been anchored in traditional medicine. It is thus a treatment that uses innovative and at the same time proven effective approaches.

Write us,

we will be happy to connect with you




    UNIQUE THERAPEUTICS GLOBAL s.r.o.

    Na Luhách 1559/14
    400 01 Ústí nad Labem
    Czech Republic

    info@uniquetherepeutics.com
    +420 774 668 177

    Our Team

    Radek Hlaváček

    One of the founding members of Unique Therapeutics, a Canadian company based in Ústí nad Labem, the city where Radek lived until he was 19 years old. As an immigrant he moved to Switzerland and later to Canada, where he has lived with his wife since 1991. He started cultivating cannabis and using the flowers and extracts of Cannabis for medical purposes in 2000 after obtaining his MMAR License (Marijuana Medical Access Regulations).

    Ivana Bednářová

    Ivana Bednářová has twenty years of experience in sales, marketing and public relations, having held senior positions in a number of international companies during her career. Within her own marketing and PR agency, she founded and led several successful projects related to healthy lifestyle and international certification of food supplements and food. A graduate of Anglo American University with a degree in Economics, she has three children and her hobbies include sports, travel and gastronomy.

    Liam Duff

    As the Chief Science and Technology Officer at Unique Therapeutics, Liam is responsible for the development, testing, manufacturing and compliance of our manufacturing processes as well as day-to-day operations. Intellectual property and technology are at the core of our company Unique Therapeutics and Liam is responsible for ensuring we are always at the forefront of the most effective ways to deliver cannabinoids into the body and ensuring our quality is the best it can be.

    Ranjit S. Bhardwaj

    Ranjit S. Bhardwaj after studying biomedical sciences in immunology, cancer immunobiology and regenerative medicine has specialized and qualified in cancer immunobiology and regenerative medicine, cellular and molecular pathology. Dr. Ranjit Bhardwaj is active in a network of cannabis physicians and prescribers, is involved in clinical research projects at universities and R&D forums in Germany and abroad, and holds corporate advisory roles in the medical and pharmaceutical industry.

    Jakub Kryšpín

    Jakub Kryšpín is an expert in cannabis treatment. Since 2013 he has been successfully treating with the help of Phoenix Tears. Since 2021, he has continued his work in healing and scientific knowledge in cooperation with our company, focusing primarily on the treatment of oncological, but also neurodegenerative, autoimmune diseases and other diseases that somehow affect the human endocannabinoid system. Jakub has been suffering from multiple sclerosis since 2006 and was once in a wheelchair. He claims that cannabis is the most important herb on planet Earth, given its wide range of uses.

    Ing. Miloš Podolský

    Miloš Podolský became a new member of the Unique Therapeutics Global team in 2024. Miloš's experience in international sales and marketing has become a welcome asset not only for the company. Unique, but also for our international partners. Unique Therapeutics Global has its roots and experience in Canada where the founding members of Unique have been involved since 2012 in the development of cannabis legalization legislation and conditions for cultivation and processing of medical cannabis. This experience and knowledge helps us to establish cooperation with foreign partners who are thinking about legalization and medical cannabis in their country or are only in the beginning. By combining the many years of knowledge of our company and the business experience of Milos Podolski, we are able to offer a wide range of options both in terms of legislation and production. This places Unique Therapeutics Global with its SEED TO SALE program among the world leaders in the cannabis industry. Milos' hobbies include sailing, boating, sports car racing and traveling.

    John Wanyu

    Current research on CBD shows that cannabis could help African nations with the disease sickle cell anemia. Meetings held with Ugandan government officials in October 2024 have provided the impetus and foundation for the preparation of clinical trials to test the efficacy of Unique Therapeutics' liposomal formulations in the treatment of Sickle Cell Disease. Johnny will be our coordinator and representative in Uganda. His role is to prepare the conditions for the clinical trial, conduct the clinical trial in collaboration with the collaborating university hospital and the Ministry of Health. We hope that our data will confirm the efficacy of Unique T products in the treatment, Unique T will ensure the production and distribution of the drug product in Uganda.